Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico

C Neslusan, A R Teschemaker,P Johansen,Michael Willis,Atanacio Valenciamendoza, Andrea Puig

Value in Health Regional Issues（2015）

引用 19|浏览3

暂无评分

摘要

In Mexico, both doses of canagliflozin are likely to be cost-effective versus sitagliptin in patients with T2DM who have inadequate glucose control on metformin, primarily because of better biomarker control and higher QALYs.

查看译文

关键词

cost-effectiveness,dipeptidyl peptidase-4 inhibitor,SGLT2 inhibitor,type 2 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要